
Chapter 22
NATIONAL DRUG CONTROL POLICY
 Definitions
“(a)
 
In General
.—
The Director of the Office of National Drug Control Policy shall provide for or shall enter into an agreement with a non-profit corporation that is described in section 501(c)(3) of the Internal Revenue Code of 1986 [
26 U.S.C. 501(c)(3)
] and exempt from tax under section 501(a) of such Code to—
“(1)
 advise States on establishing laws and policies to address alcohol and other drug issues, based on the model State drug laws developed by the President’s Commission on Model State Drug Laws in 1993; and




“(2)
 revise such model State drug laws and draft supplementary model State laws to take into consideration changes in the alcohol and drug abuse problems in the State involved.




“(b)
 
Authorization of Appropriations
.—
There is authorized to be appropriated to carry out this subsection [probably should be “section”] $1,500,000 for each of fiscal years 2007 through 2011.”


 Office of National Drug Control Policy
(a)
 Establishment of Office
There is established in the Executive Office of the President an Office of National Drug Control Policy, which shall—
(1)
 develop national drug control policy;




(2)
 coordinate and oversee the implementation of the national drug control policy;




(3)
 assess and certify the adequacy of National Drug Control Programs and the budget for those programs; and




(4)
 evaluate the effectiveness of the national drug control policy and the National Drug Control Program agencies’ programs, by developing and applying specific goals and performance measurements.





When developing the national drug control policy, any policy of the Director relating to syringe exchange programs for intravenous drug users shall be based on the best available medical and scientific evidence regarding their effectiveness in promoting individual health and preventing the spread of infectious disease, and their impact on drug addiction and use. In making any policy relating to syringe exchange programs, the Director shall consult with the National Institutes of Health and the National Academy of Sciences.


(b)
 Director of National Drug Control Policy and Deputy Directors
(1)
 Director
There shall be a Director of National Drug Control Policy who shall head the Office (referred to in this chapter as the “Director”) and shall hold the same rank and status as the head of an executive department listed in 
section 101 of title 5
.






(2)
 Deputy Director
There shall be a Deputy Director of National Drug Control Policy who shall report directly to the Director (referred to in this chapter as the “Deputy Director”).






(3)
 Other Deputy Directors
(A)
 In general
There shall be a Deputy Director for Demand Reduction, a Deputy Director for Supply Reduction, and a Deputy Director for State, Local, and Tribal Affairs.






(B)
 Reporting
The Deputy Director for Demand Reduction, the Deputy Director for Supply Reduction, and the Deputy Director for State, Local, and Tribal Affairs shall report directly to the Deputy Director of the Office of National Drug Control Policy.






(C)
 Deputy Director for Demand Reduction
The Deputy Director for Demand Reduction shall be responsible for the activities in subparagraphs (A) through (H) of section 1701(1) 
1
1
 See References in Text note below.
 of this title.






(D)
 Deputy Director for Supply Reduction
The Deputy Director for Supply Reduction shall—
(i)
 have substantial experience and expertise in drug interdiction and other supply reduction activities; and




(ii)
 be responsible for the activities in subparagraphs (A) through (C) in 
section 1701(11) of this title
.






(E)
 Deputy Director for State, Local, and Tribal Affairs
The Deputy Director for State, Local, and Tribal Affairs shall be responsible for the activities—
(i)
 in subparagraphs (A) through (D) of 
section 1701(10) of this title
;




(ii)
 in 
section 1706 of this title
, the High Intensity Drug Trafficking Areas Program; and




(iii)
 in 
section 1707 of this title
, the Counterdrug Technology Assessment Center.








(c)
 Access by Congress
The location of the Office in the Executive Office of the President shall not be construed as affecting access by Congress, or any committee of the House of Representatives or the Senate, to any—
(1)
 information, document, or study in the possession of, or conducted by or at the direction of the Director; or




(2)
 personnel of the Office.




(d)
 Office of National Drug Control Policy Gift Fund
(1)
 Establishment
There is established in the Treasury of the United States a fund for the receipt of gifts, both real and personal, for the purpose of aiding or facilitating the work of the Office under 
section 1703(c) of this title
.






(2)
 Contributions
The Office may accept, hold, and administer contributions to the Fund.






(3)
 Use of amounts deposited
Amounts deposited in the Fund are authorized to be appropriated, to remain available until expended for authorized purposes at the discretion of the Director.






 Appointment and duties of Director and Deputy Directors
(a)
 Appointment
(1)
 In general
(A)
 Director
The Director shall be appointed by the President, by and with the advice and consent of the Senate, and shall serve at the pleasure of the President.






(B)
 Deputy Directors
The Deputy Director of National Drug Control Policy, Deputy Director for Demand Reduction, the Deputy Director for Supply Reduction, and the Deputy Director for State, Local, and Tribal Affairs shall each be appointed by the President and serve at the pleasure of the President.






(C)
 Deputy Director for Demand Reduction
In appointing the Deputy Director for Demand Reduction under this paragraph, the President shall take into consideration the scientific, educational, or professional background of the individual, and whether the individual has experience in the fields of substance abuse prevention, education, or treatment.








(2)
 Duties of Deputy Director of National Drug Control Policy
The Deputy Director of National Drug Control Policy shall—
(A)
 carry out the duties and powers prescribed by the Director; and




(B)
 serve as the Director in the absence of the Director or during any period in which the office of the Director is vacant.






(3)
 Acting Director
If the Director dies, resigns, or is otherwise unable to perform the functions and duties of the office, the Deputy Director shall perform the functions and duties of the Director temporarily in an acting capacity pursuant to subchapter III of chapter 33 of title 5.






(4)
 Prohibition
No person shall serve as Director or a Deputy Director while serving in any other position in the Federal Government.






(5)
 Prohibition on political campaigning
Any officer or employee of the Office who is appointed to that position by the President, by and with the advice and consent of the Senate, may not participate in Federal election campaign activities, except that such official is not prohibited by this paragraph from making contributions to individual candidates.






(b)
 Responsibilities
The Director—
(1)
 shall assist the President in the establishment of policies, goals, objectives, and priorities for the National Drug Control Program;




(2)
 shall promulgate the National Drug Control Strategy under 
section 1705(a) of this title
 and each report under 
section 1705(b) of this title
 in accordance with 
section 1705 of this title
;




(3)
 shall coordinate and oversee the implementation by the National Drug Control Program agencies of the policies, goals, objectives, and priorities established under paragraph (1) and the fulfillment of the responsibilities of such agencies under the National Drug Control Strategy and make recommendations to National Drug Control Program agency heads with respect to implementation of Federal counter-drug programs;




(4)
 shall make such recommendations to the President as the Director determines are appropriate regarding changes in the organization, management, and budgets of National Drug Control Program agencies, and changes in the allocation of personnel to and within those departments and agencies, to implement the policies, goals, priorities, and objectives established under paragraph (1) and the National Drug Control Strategy;




(5)
 shall consult with and assist State and local governments with respect to the formulation and implementation of National Drug Control Policy and their relations with the National Drug Control Program agencies;




(6)
 shall appear before duly constituted committees and subcommittees of the House of Representatives and of the Senate to represent the drug policies of the executive branch;




(7)
 shall notify any National Drug Control Program agency if its policies are not in compliance with the responsibilities of the agency under the National Drug Control Strategy, transmit a copy of each such notification to the President and the appropriate congressional committees, and maintain a copy of each such notification;




(8)
 shall provide, by July 1 of each year, budget recommendations, including requests for specific initiatives that are consistent with the priorities of the President under the National Drug Control Strategy, to the heads of departments and agencies with responsibilities under the National Drug Control Program, which recommendations shall—
(A)
 apply to the next budget year scheduled for formulation under chapter 11 of title 31, and each of the 4 subsequent fiscal years; and




(B)
 address funding priorities developed in the National Drug Control Strategy;






(9)
 may serve as representative of the President in appearing before Congress on all issues relating to the National Drug Control Program;




(10)
 shall, in any matter affecting national security interests, work in conjunction with the Assistant to the President for National Security Affairs;




(11)
 may serve as spokesperson of the Administration on drug issues;




(12)
 shall ensure that no Federal funds appropriated to the Office of National Drug Control Policy shall be expended for any study or contract relating to the legalization (for a medical use or any other use) of a substance listed in schedule I of 
section 812 of this title
 and take such actions as necessary to oppose any attempt to legalize the use of a substance (in any form) that—
(A)
 is listed in schedule I of 
section 812 of this title
; and




(B)
 has not been approved for use for medical purposes by the Food and Drug Administration;






(13)
 shall require each National Drug Control Program agency to submit to the Director on an annual basis an evaluation of progress by the agency with respect to drug control program goals using the performance measures for the agency developed under 
section 1705(c) of this title
, including progress with respect to—
(A)
 success in reducing domestic and foreign sources of illegal drugs;




(B)
 success in protecting the borders of the United States (and in particular the Southwestern border of the United States) from penetration by illegal narcotics;




(C)
 success in reducing violent crime associated with drug use in the United States;




(D)
 success in reducing the negative health and social consequences of drug use in the United States; and




(E)
 implementation of drug treatment and prevention programs in the United States and improvements in the adequacy and effectiveness of such programs;






(14)
 shall submit to the appropriate congressional committees on an annual basis, not later than 60 days after the date of the last day of the applicable period, a summary of—
(A)
 each of the evaluations received by the Director under paragraph (13); and




(B)
 the progress of each National Drug Control Program agency toward the drug control program goals of the agency using the performance measures for the agency developed under 
section 1705(c) of this title
;






(15)
 shall ensure that drug prevention and drug treatment research and information is effectively disseminated by National Drug Control Program agencies to State and local governments and nongovernmental entities involved in demand reduction by—
(A)
 encouraging formal consultation between any such agency that conducts or sponsors research, and any such agency that disseminates information in developing research and information product development agendas;




(B)
 encouraging such agencies (as appropriate) to develop and implement dissemination plans that specifically target State and local governments and nongovernmental entities involved in demand reduction; and




(C)
 supporting the substance abuse information clearinghouse administered by the Administrator of the Substance Abuse and Mental Health Services Administration and established in 
section 290aa(d)(16) of title 42
 by—
(i)
 encouraging all National Drug Control Program agencies to provide all appropriate and relevant information; and




(ii)
 supporting the dissemination of information to all interested entities;








(16)
 shall coordinate with the private sector to promote private research and development of medications to treat addiction;




(17)
 shall seek the support and commitment of State, local, and tribal officials in the formulation and implementation of the National Drug Control Strategy;




(18)
 shall monitor and evaluate the allocation of resources among Federal law enforcement agencies in response to significant local and regional drug trafficking and production threats;




(19)
 shall submit an annual report to Congress detailing how the Office of National Drug Control Policy has consulted with and assisted State, local, and tribal governments with respect to the formulation and implementation of the National Drug Control Strategy and other relevant issues; and




(20)
 shall, within 1 year after 
December 29, 2006
, report to Congress on the impact of each Federal drug reduction strategy upon the availability, addiction rate, use rate, and other harms of illegal drugs.




(c)
 National Drug Control Program budget
(1)
 Responsibilities of National Drug Control Program agencies
(A)
 In general
For each fiscal year, the head of each department, agency, or program of the Federal Government with responsibilities under the National Drug Control Program Strategy shall transmit to the Director a copy of the proposed drug control budget request of the department, agency, or program at the same time as that budget request is submitted to their superiors (and before submission to the Office of Management and Budget) in the preparation of the budget of the President submitted to Congress under 
section 1105(a) of title 31
.






(B)
 Submission of drug control budget requests
The head of each National Drug Control Program agency shall ensure timely development and submission to the Director of each proposed drug control budget request transmitted pursuant to this paragraph, in such format as may be designated by the Director with the concurrence of the Director of the Office of Management and Budget.






(C)
 Content of drug control budget requests
A drug control budget request submitted by a department, agency, or program under this paragraph shall include all requests for funds for any drug control activity undertaken by that department, agency, or program, including demand reduction, supply reduction, and State, local, and tribal affairs, including any drug law enforcement activities. If an activity has both drug control and nondrug control purposes or applications, the department, agency, or program shall estimate by a documented calculation the total funds requested for that activity that would be used for drug control, and shall set forth in its request the basis and method for making the estimate.








(2)
 National Drug Control Program budget proposal
For each fiscal year, following the transmission of proposed drug control budget requests to the Director under paragraph (1), the Director shall, in consultation with the head of each National Drug Control Program agency and the head of each major national organization that represents law enforcement officers, agencies, or associations—
(A)
 develop a consolidated National Drug Control Program budget proposal designed to implement the National Drug Control Strategy and to inform Congress and the public about the total amount proposed to be spent on all supply reduction, demand reduction, State, local, and tribal affairs, including any drug law enforcement, and other drug control activities by the Federal Government, which shall conform to the content requirements set forth in paragraph (1)(C);




(B)
 submit the consolidated budget proposal to the President; and




(C)
 after submission under subparagraph (B), submit the consolidated budget proposal to Congress.






(3)
 Review and certification of budget requests and budget submissions of National Drug Control Program agencies
(A)
 In general
The Director shall review each drug control budget request submitted to the Director under paragraph (1).






(B)
 Review of budget requests
(i)
 Inadequate requests
If the Director concludes that a budget request submitted under paragraph (1) is inadequate, in whole or in part, to implement the objectives of the National Drug Control Strategy with respect to the department, agency, or program at issue for the year for which the request is submitted, the Director shall submit to the head of the applicable National Drug Control Program agency a written description of funding levels and specific initiatives that would, in the determination of the Director, make the request adequate to implement those objectives.






(ii)
 Adequate requests
If the Director concludes that a budget request submitted under paragraph (1) is adequate to implement the objectives of the National Drug Control Strategy with respect to the department, agency, or program at issue for the year for which the request is submitted, the Director shall submit to the head of the applicable National Drug Control Program agency a written statement confirming the adequacy of the request.






(iii)
 Record
The Director shall maintain a record of each description submitted under clause (i) and each statement submitted under clause (ii).








(C)
 Specific requests
The Director shall not confirm the adequacy of any budget request that—
(i)
 requests funding for Federal law enforcement activities that do not adequately compensate for transfers of drug enforcement resources and personnel to law enforcement and investigation activities;




(ii)
 requests funding for law enforcement activities on the borders of the United States that do not adequately direct resources to drug interdiction and enforcement;




(iii)
 requests funding for drug treatment activities that do not provide adequate results and accountability measures;




(iv)
 requests funding for any activities of the Safe and Drug-Free Schools Program that do not include a clear anti-drug message or purpose intended to reduce drug use;




(v)
 requests funding for drug treatment activities that do not adequately support and enhance Federal drug treatment programs and capacity;




(vi)
 requests funding for fiscal year 2007 for activities of the Department of Education, unless it is accompanied by a report setting forth a plan for providing expedited consideration of student loan applications for all individuals who submitted an application for any Federal grant, loan, or work assistance that was rejected or denied pursuant to 1091(r)(1) 
1
1
 So in original. Probably should be preceded by “section”.
 of title 20 by reason of a conviction for a drug-related offense not occurring during a period of enrollment for which the individual was receiving any Federal grant, loan, or work assistance; and




(vii)
 requests funding for the operations and management of the Department of Homeland Security that does not include a specific request for funds for the Office of Counternarcotics Enforcement to carry out its responsibilities under 
section 458 of title 6
.






(D)
 Agency response
(i)
 In general
The head of a National Drug Control Program agency that receives a description under subparagraph (B)(i) shall include the funding levels and initiatives described by the Director in the budget submission for that agency to the Office of Management and Budget.






(ii)
 Impact statement
The head of a National Drug Control Program agency that has altered its budget submission under this subparagraph shall include as an appendix to the budget submission for that agency to the Office of Management and Budget an impact statement that summarizes—
(I)
 the changes made to the budget under this subparagraph; and




(II)
 the impact of those changes on the ability of that agency to perform its other responsibilities, including any impact on specific missions or programs of the agency.






(iii)
 Congressional notification
The head of a National Drug Control Program agency shall submit a copy of any impact statement under clause (ii) to the Senate and the House of Representatives and the appropriate congressional committees, at the time the budget for that agency is submitted to Congress under 
section 1105(a) of title 31
.








(E)
 Certification of budget submissions
(i)
 In general
At the time a National Drug Control Program agency submits its budget request to the Office of Management and Budget, the head of the National Drug Control Program agency shall submit a copy of the budget request to the Director.






(ii)
 Certification
The Director—
(I)
 shall review each budget submission submitted under clause (i); and




(II)
 based on the review under subclause (I), if the Director concludes that the budget submission of a National Drug Control Program agency does not include the funding levels and initiatives described under subparagraph (B)—
(aa)
 may issue a written decertification of that agency’s budget; and




(bb)
 in the case of a decertification issued under item (aa), shall submit to the Senate and the House of Representatives and the appropriate congressional committees, a copy of—
(aaa)
 the decertification issued under item (aa);




(bbb)
 the description made under subparagraph (B); and




(ccc)
 the budget recommendations made under subsection (b)(8) of this section.














(4)
 Reprogramming and transfer requests
(A)
 In general
No National Drug Control Program agency shall submit to Congress a reprogramming or transfer request with respect to any amount of appropriated funds in an amount exceeding $1,000,000 that is included in the National Drug Control Program budget unless the request has been approved by the Director. If the Director has not responded to a request for reprogramming subject to this subparagraph within 30 days after receiving notice of the request having been made, the request shall be deemed approved by the Director under this subparagraph and forwarded to Congress.






(B)
 Appeal
The head of any National Drug Control Program agency may appeal to the President any disapproval by the Director of a reprogramming or transfer request under this paragraph.








(d)
 Powers of the Director
In carrying out subsection (b) of this section, the Director may—
(1)
 select, appoint, employ, and fix compensation of such officers and employees of the Office as may be necessary to carry out the functions of the Office under this chapter;




(2)
 subject to subsection (e)(3) of this section, request the head of a department or agency, or program of the Federal Government to place department, agency, or program personnel who are engaged in drug control activities on temporary detail to another department, agency, or program in order to implement the National Drug Control Strategy, and the head of the department or agency shall comply with such a request;




(3)
 use for administrative purposes, on a reimbursable basis, the available services, equipment, personnel, and facilities of Federal, State, and local agencies;




(4)
 procure the services of experts and consultants in accordance with 
section 3109 of title 5
, relating to appointments in the Federal Service, at rates of compensation for individuals not to exceed the daily equivalent of the rate of pay payable under level IV of the Executive Schedule under 
section 5311 of title 5
;




(5)
 accept and use gifts and donations of property from Federal, State, and local government agencies, and from the private sector, as authorized in 
section 1702(d) of this title
;




(6)
 use the mails in the same manner as any other department or agency of the executive branch;




(7)
 monitor implementation of the National Drug Control Program, including—
(A)
 conducting program and performance audits and evaluations; and




(B)
 requesting assistance from the Inspector General of the relevant agency in such audits and evaluations;






(8)
 transfer funds made available to a National Drug Control Program agency for National Drug Control Strategy programs and activities to another account within such agency or to another National Drug Control Program agency for National Drug Control Strategy programs and activities, except that—
(A)
 the authority under this paragraph may be limited in an annual appropriations Act or other provision of Federal law;




(B)
 the Director may exercise the authority under this paragraph only with the concurrence of the head of each affected agency;




(C)
 in the case of an interagency transfer, the total amount of transfers under this paragraph may not exceed 3 percent of the total amount of funds made available for National Drug Control Strategy programs and activities to the agency from which those funds are to be transferred;




(D)
 funds transferred to an agency under this paragraph may only be used to increase the funding for programs or activities authorized by law; and




(E)
 the Director shall—
(i)
 submit to Congress, including to the Committees on Appropriations of the Senate and the House of Representatives, the authorizing committees for the Office, and any other applicable committees of jurisdiction, a reprogramming or transfer request in advance of any transfer under this paragraph in accordance with the regulations of the affected agency or agencies; and




(ii)
 annually submit to Congress a report describing the effect of all transfers of funds made pursuant to this paragraph or subsection (c)(4) of this section during the 12-month period preceding the date on which the report is submitted;








(9)
 issue to the head of a National Drug Control Program agency a fund control notice described in subsection (f) of this section to ensure compliance with the National Drug Control Program Strategy and notify the appropriate congressional committees of any fund control notice issued in accordance with subsection (f)(5);




(10)
 participate in the drug certification process pursuant to 
section 2291j of title 22
 and 
section 2291j–1 of title 22
.




(e)
 Personnel detailed to Office
(1)
 Evaluations
Notwithstanding any provision of chapter 43 of title 5, the Director shall perform the evaluation of the performance of any employee detailed to the Office for purposes of the applicable performance appraisal system established under such chapter for any rating period, or part thereof, that such employee is detailed to such office.






(2)
 Compensation
(A)
 Bonus payments
Notwithstanding any other provision of law, the Director may provide periodic bonus payments to any employee detailed to the Office.






(B)
 Restrictions
An amount paid under this paragraph to an employee for any period—
(i)
 shall not be greater than 20 percent of the basic pay paid or payable to such employee for such period; and




(ii)
 shall be in addition to the basic pay of such employee.






(C)
 Aggregate amount
The aggregate amount paid during any fiscal year to an employee detailed to the Office as basic pay, awards, bonuses, and other compensation shall not exceed the annual rate payable at the end of such fiscal year for positions at level III of the Executive Schedule.








(3)
 Maximum number of detailees
The maximum number of personnel who may be detailed to another department or agency (including the Office) under subsection (d)(2) of this section during any fiscal year is—
(A)
 for the Department of Defense, 50; and




(B)
 for any other department or agency, 10.






(f)
 Fund control notices
(1)
 In general
A fund control notice may direct that all or part of an amount appropriated to the National Drug Control Program agency account be obligated by—
(A)
 months, fiscal year quarters, or other time periods; and




(B)
 activities, functions, projects, or object classes.






(2)
 Unauthorized obligation or expenditure prohibited
An officer or employee of a National Drug Control Program agency shall not make or authorize an expenditure or obligation contrary to a fund control notice issued by the Director.






(3)
 Disciplinary action for violation
In the case of a violation of paragraph (2) by an officer or employee of a National Drug Control Program agency, the head of the agency, upon the request of and in consultation with the Director, may subject the officer or employee to appropriate administrative discipline, including, when circumstances warrant, suspension from duty without pay or removal from office.






(4)
 
2
2
 So in original. Two pars. (4) have been enacted.
 Congressional notice
A copy of each fund control notice shall be transmitted to the appropriate congressional committees.






(5)
 
3
3
 So in original. Two pars. (5) have been enacted.
 Restrictions
The Director shall not issue a fund control notice to direct that all or part of an amount appropriated to the National Drug Control Program agency account be obligated, modified, or altered in any manner—
(A)
 contrary, in whole or in part, to a specific appropriation; or




(B)
 contrary, in whole or in part, to the expressed intent of Congress.






(4)
 
2
 Congressional notice
A copy of each fund control notice shall be transmitted to the appropriate congressional committees.






(5)
 
3
 Restrictions
The Director shall not issue a fund control notice to direct that all or part of an amount appropriated to the National Drug Control Program agency account be obligated, modified, or altered in any manner contrary, in whole or in part, to a specific appropriation or statute.






(g)
 Inapplicability to certain programs
The provisions of this section shall not apply to the National Intelligence Program, the Joint Military Intelligence Program, and Tactical and Related Activities, unless such program or an element of such program is designated as a National Drug Control Program—
(1)
 by the President; or




(2)
 jointly by—
(A)
 in the case of the National Intelligence Program, the Director and the Director of National Intelligence; or




(B)
 in the case of the Joint Military Intelligence Program and Tactical and Related Activities, the Director, the Director of National Intelligence, and the Secretary of Defense.






(h)
 Construction
Nothing in this chapter shall be construed as derogating the authorities and responsibilities of the Director of National Intelligence or the Director of the Central Intelligence Agency contained in the National Security Act of 1947 [
50 U.S.C. 3001
 et seq.], the Central Intelligence Agency Act of 1949 [
50 U.S.C. 3501
 et seq.], or any other law.




 Coordination with National Drug Control Program agencies in demand reduction, supply reduction, and State and local affairs
(a)
 Access to information
(1)
 In general
Upon the request of the Director, the head of any National Drug Control Program agency shall cooperate with and provide to the Director any statistics, studies, reports, and other information prepared or collected by the agency concerning the responsibilities of the agency under the National Drug Control Strategy that relate to—
(A)
 drug control; or




(B)
 the manner in which amounts made available to that agency for drug control are being used by that agency.






(2)
 Protection of intelligence information
(A)
 In general
The authorities conferred on the Office and the Director by this chapter shall be exercised in a manner consistent with provisions of the National Security Act of 1947 [
50 U.S.C. 3001
 et seq.]. The Director of National Intelligence shall prescribe such regulations as may be necessary to protect information provided pursuant to this chapter regarding intelligence sources and methods.






(B)
 Duties of Director
The Director of National Intelligence and the Director of the Central Intelligence Agency shall, to the maximum extent practicable in accordance with subparagraph (A), render full assistance and support to the Office and the Director.








(3)
 Required reports
(A)
 Secretaries of the Interior and Agriculture
Not later than July 1 of each year, the Secretaries of Agriculture and the Interior shall jointly submit to the Director and the appropriate congressional committees an assessment of the quantity of illegal drug cultivation and manufacturing in the United States on lands owned or under the jurisdiction of the Federal Government for the preceding year.






(B)
 Secretary of Homeland Security
Not later than July 1 of each year, the Secretary of Homeland Security shall submit to the Director and the appropriate congressional committees information for the preceding year regarding—
(i)
 the number and type of seizures of drugs by each component of the Department of Homeland Security seizing drugs, as well as statistical information on the geographic areas of such seizures; and




(ii)
 the number of air and maritime patrol hours primarily dedicated to drug supply reduction missions undertaken by each component of the Department of Homeland Security.






(C)
 Secretary of Defense
The Secretary of Defense shall, by July 1 of each year, submit to the Director and the appropriate congressional committees information for the preceding year regarding the number of air and maritime patrol hours primarily dedicated to drug supply reduction missions undertaken by each component of the Department of Defense.






(D)
 Attorney General
The Attorney General shall, by July 1 of each year, submit to the Director and the appropriate congressional committees information for the preceding year regarding the number and type of—
(i)
 arrests for drug violations;




(ii)
 prosecutions for drug violations by United States Attorneys; and




(iii)
 seizures of drugs by each component of the Department of Justice seizing drugs, as well as statistical information on the geographic areas of such seizures.








(b)
 Certification of policy changes to Director
(1)
 In general
Subject to paragraph (2), the head of a National Drug Control Program agency shall, unless exigent circumstances require otherwise, notify the Director in writing regarding any proposed change in policies relating to the activities of that agency under the National Drug Control Program prior to implementation of such change. The Director shall promptly review such proposed change and certify to the head of that agency in writing whether such change is consistent with the National Drug Control Strategy.






(2)
 Exception
If prior notice of a proposed change under paragraph (1) is not practicable—
(A)
 the head of the National Drug Control Program agency shall notify the Director of the proposed change as soon as practicable; and




(B)
 upon such notification, the Director shall review the change and certify to the head of that agency in writing whether the change is consistent with the National Drug Control Strategy.






(c)
 General Services Administration
The Administrator of General Services shall provide to the Director, on a reimbursable basis, such administrative support services as the Director may request.




(d)
 Accounting of funds expended
The Director shall—
(A)
 require the National Drug Control Program agencies to submit to the Director not later than February 1 of each year a detailed accounting of all funds expended by the agencies for National Drug Control Program activities during the previous fiscal year, and require such accounting to be authenticated by the Inspector General for each agency prior to submission to the Director; and




(B)
 submit to Congress not later than April 1 of each year the information submitted to the Director under subparagraph (A).




 Development, submission, implementation, and assessment of National Drug Control Strategy
(a)
 Timing, contents, and process for development and submission of National Drug Control Strategy
(1)
 Timing
Not later than February 1 of each year, the President shall submit to Congress a National Drug Control Strategy, which shall set forth a comprehensive plan for the year to reduce illicit drug use and the consequences of such illicit drug use in the United States by limiting the availability of, and reducing the demand for, illegal drugs.






(2)
 Contents
(A)
 In general
The National Drug Control Strategy submitted under paragraph (1) shall include the following:
(i)
 Comprehensive, research-based, long-range, quantifiable goals for reducing illicit drug use and the consequences of illicit drug use in the United States.




(ii)
 Annual quantifiable and measurable objectives and specific targets to accomplish long-term quantifiable goals that the Director determines may be achieved during each year beginning on the date on which the National Drug Control Strategy is submitted.




(iii)
 A 5-year projection for program and budget priorities.




(iv)
 A review of international, State, local, and private sector drug control activities to ensure that the United States pursues coordinated and effective drug control at all levels of government.




(v)
 An assessment of current illicit drug use (including inhalants and steroids) and availability, impact of illicit drug use, and treatment availability, which assessment shall include—
(I)
 estimates of drug prevalence and frequency of use as measured by national, State, and local surveys of illicit drug use and by other special studies of nondependent and dependent illicit drug use;




(II)
 illicit drug use in the workplace and the productivity lost by such use; and




(III)
 illicit drug use by arrestees, probationers, and parolees.






(vi)
 An assessment of the reduction of illicit drug availability, as measured by—
(I)
 the quantities of cocaine, heroin, marijuana, methamphetamine, ecstasy, and other drugs available for consumption in the United States;




(II)
 the amount of marijuana, cocaine, heroin, methamphetamine, ecstasy, and precursor chemicals and other drugs entering the United States;




(III)
 the number of illicit drug manufacturing laboratories seized and destroyed and the number of hectares of marijuana, poppy, and coca cultivated and destroyed domestically and in other countries;




(IV)
 the number of metric tons of marijuana, heroin, cocaine, and methamphetamine seized and other drugs; and




(V)
 changes in the price and purity of heroin, methamphetamine, and cocaine, changes in the price of ecstasy, and changes in tetrahydrocannabinol level of marijuana and other drugs.






(vii)
 An assessment of the reduction of the consequences of illicit drug use and availability, which shall include—
(I)
 the burden illicit drug users placed on hospital emergency departments in the United States, such as the quantity of illicit drug-related services provided;




(II)
 the annual national health care cost of illicit drug use; and




(III)
 the extent of illicit drug-related crime and criminal activity.






(viii)
 A determination of the status of drug treatment in the United States, by assessing—
(I)
 public and private treatment utilization; and




(II)
 the number of illicit drug users the Director estimates meet diagnostic criteria for treatment.






(ix)
 A review of the research agenda of the Counterdrug Technology Assessment Center to reduce the availability and abuse of drugs.




(x)
 A summary of the efforts made to coordinate with private sector entities to conduct private research and development of medications to treat addiction by—
(I)
 screening chemicals for potential therapeutic value;




(II)
 developing promising compounds;




(III)
 conducting clinical trials;




(IV)
 seeking Food and Drug Administration approval for drugs to treat addiction;




(V)
 marketing the drug for the treatment of addiction;




(VI)
 urging physicians to use the drug in the treatment of addiction; and




(VII)
 encouraging insurance companies to reimburse the cost of the drug for the treatment of addiction.






(xi)
 An assessment of Federal effectiveness in achieving the National Drug Control Strategy for the previous year, including a specific evaluation of whether the objectives and targets for reducing illicit drug use for the previous year were met and reasons for the success or failure of the previous year’s Strategy.




(xii)
 A general review of the status of, and trends in, demand reduction activities by private sector entities and community-based organizations, including faith-based organizations, to determine their effectiveness and the extent of cooperation, coordination, and mutual support between such entities and organizations and Federal, State, local, and tribal government agencies.




(xiii)
 Such additional statistical data and information as the Director considers appropriate to demonstrate and assess trends relating to illicit drug use, the effects and consequences of illicit drug use (including the effects on children of substance abusers), supply reduction, demand reduction, drug-related law enforcement, and the implementation of the National Drug Control Strategy.




(xiv)
 A supplement reviewing the activities of each individual National Drug Control Program agency during the previous year with respect to the National Drug Control Strategy and the Director’s assessment of the progress of each National Drug Control Program agency in meeting its responsibilities under the National Drug Control Strategy.






(B)
 Classified information
Any contents of the National Drug Control Strategy that involve information properly classified under criteria established by an Executive order shall be presented to Congress separately from the rest of the National Drug Control Strategy.






(C)
 Selection of data and information
In selecting data and information for inclusion under subparagraph (A), the Director shall ensure—
(i)
 the inclusion of data and information that will permit analysis of current trends against previously compiled data and information where the Director believes such analysis enhances long-term assessment of the National Drug Control Strategy; and




(ii)
 the inclusion of data and information to permit a standardized and uniform assessment of the effectiveness of drug treatment programs in the United States.








(3)
 Process for development and submission
In developing and effectively implementing the National Drug Control Strategy, the Director—
(A)
 shall consult with—
(i)
 the heads of the National Drug Control Program agencies;




(ii)
 Congress;




(iii)
 State, local, and tribal officials;




(iv)
 private citizens and organizations, including community and faith-based organizations with experience and expertise in demand reduction;




(v)
 private citizens and organizations with experience and expertise in supply reduction; and




(vi)
 appropriate representatives of foreign governments;






(B)
 in satisfying the requirements of subparagraph (A), shall ensure, to the maximum extent possible, that State, local, and tribal officials and relevant private organizations commit to support and take steps to achieve the goals and objectives of the National Drug Control Strategy;




(C)
 with the concurrence of the Attorney General, may require the El Paso Intelligence Center to undertake specific tasks or projects to support or implement the National Drug Control Strategy; and




(D)
 with the concurrence of the Director of National Intelligence and the Attorney General, may request that the National Drug Intelligence Center undertake specific tasks or projects to support or implement the National Drug Control Strategy.






(b)
 Submission of revised strategy
The President may submit to Congress a revised National Drug Control Strategy that meets the requirements of this section—
(1)
 at any time, upon a determination of the President, in consultation with the Director, that the National Drug Control Strategy in effect is not sufficiently effective; or




(2)
 if a new President or Director takes office.




(c)
 Performance measurement system
Not later than February 1 of each year, the Director shall submit to Congress as part of the National Drug Control Strategy, a description of a national drug control performance measurement system, that—
(1)
 develops 2-year and 5-year performance measures and targets for each National Drug Control Strategy goal and objective established for reducing drug use, availability, and the consequences of drug use;




(2)
 describes the sources of information and data that will be used for each performance measure incorporated into the performance measurement system;




(3)
 identifies major programs and activities of the National Drug Control Program agencies that support the goals and annual objectives of the National Drug Control Strategy;




(4)
 evaluates the contribution of demand reduction and supply reduction activities as defined in 
section 1701 of this title
 implemented by each National Drug Control Program agency in support of the National Drug Control Strategy;




(5)
 monitors consistency between the drug-related goals and objectives of the National Drug Control Program agencies and ensures that each agency’s goals and budgets support and are fully consistent with the National Drug Control Strategy; and




(6)
 coordinates the development and implementation of national drug control data collection and reporting systems to support policy formulation and performance measurement, including an assessment of—
(A)
 the quality of current drug use measurement instruments and techniques to measure supply reduction and demand reduction activities;




(B)
 the adequacy of the coverage of existing national drug use measurement instruments and techniques to measure the illicit drug user population, and groups that are at risk for illicit drug use;




(C)
 the adequacy of the coverage of existing national treatment outcome monitoring systems to measure the effectiveness of drug abuse treatment in reducing illicit drug use and criminal behavior during and after the completion of substance abuse treatment; and




(D)
 the actions the Director shall take to correct any deficiencies and limitations identified pursuant to subparagraphs (A) and (B) of this subsection.






(d)
 Modifications
A description of any modifications made during the preceding year to the national drug performance measurement system described in subsection (c) shall be included in each report submitted under subsection (b).




“(a)
 
In General
.—
Not later than 120 days after the date of enactment of this Act [
Dec. 29, 2006
], and every 2 years thereafter, the Director of National Drug Control Policy shall submit to the Congress a Southwest Border Counternarcotics Strategy.


“(b)
 
Purposes
.—
The Southwest Border Counternarcotics Strategy shall—
“(1)
 set forth the Government’s strategy for preventing the illegal trafficking of drugs across the international border between the United States and Mexico, including through ports of entry and between ports of entry on that border;




“(2)
 state the specific roles and responsibilities of the relevant National Drug Control Program agencies (as defined in section 702 of the Office of National Drug Control Policy Reauthorization Act of 1998 (
21 U.S.C. 1701
)) for implementing that strategy; and




“(3)
 identify the specific resources required to enable the relevant National Drug Control Program agencies to implement that strategy.




“(c)
 
Specific Content Related to Drug Tunnels Between the United States and Mexico
.—
The Southwest Border Counternarcotics Strategy shall include—
“(1)
 a strategy to end the construction and use of tunnels and subterranean passages that cross the international border between the United States and Mexico for the purpose of illegal trafficking of drugs across such border; and




“(2)
 recommendations for criminal penalties for persons who construct or use such a tunnel or subterranean passage for such a purpose.




“(d)
 
Consultation With Other Agencies
.—
The Director shall issue the Southwest Border Counternarcotics Strategy in consultation with the heads of the relevant National Drug Control Program agencies.


“(e)
 
Limitation
.—
The Southwest Border Counternarcotics Strategy shall not change existing agency authorities or the laws governing interagency relationships, but may include recommendations about changes to such authorities or laws.


“(f)
 
Report to Congress
.—
The Director shall provide a copy of the Southwest Border Counternarcotics Strategy to the appropriate congressional committees (as defined in section 702 of the Office of National Drug Control Policy Reauthorization Act of 1998 (
21 U.S.C. 1701
)), and to the Committee on Armed Services and the Committee on Homeland Security of the House of Representatives, and the Committee on Homeland Security and Governmental Affairs and the Committee on Armed Services of the Senate.


“(g)
 
Treatment of Classified or Law Enforcement Sensitive Information
.—
Any content of the Southwest Border Counternarcotics Strategy that involves information classified under criteria established by an Executive order, or whose public disclosure, as determined by the Director or the head of any relevant National Drug Control Program agency, would be detrimental to the law enforcement or national security activities of any Federal, State, local, or tribal agency, shall be presented to Congress separately from the rest of the strategy.”


“(a)
 
Definitions
.—
In this section, the terms ‘appropriate congressional committees’, ‘Director’, and ‘National Drug Control Program agency’ have the meanings given those terms in section 702 of the Office of National Drug Control Policy Reauthorization Act of 1998 (
21 U.S.C. 1701
).


“(b)
 
Strategy
.—
Not later than 180 days after the date of enactment of this section [
Jan. 4, 2011
], and every 2 years thereafter, the Director, in consultation with the head of each relevant National Drug Control Program agency and relevant officials of States, local governments, tribal governments, and the governments of other countries, shall develop a Northern Border Counternarcotics Strategy and submit the strategy to—
“(1)
 the appropriate congressional committees (including the Committee on the Judiciary of the Senate and the Committee on the Judiciary of the House of Representatives);




“(2)
 the Committee on Armed Services, the Committee on Homeland Security and Governmental Affairs, and the Committee on Indian Affairs of the Senate; and




“(3)
 the Committee on Armed Services, the Committee on Homeland Security, and the Committee on Natural Resources of the House of Representatives.




“(c)
 
Purposes
.—
The Northern Border Counternarcotics Strategy shall—
“(1)
 set forth the strategy of the Federal Government for preventing the illegal trafficking of drugs across the international border between the United States and Canada, including through ports of entry and between ports of entry on the border;




“(2)
 state the specific roles and responsibilities of each relevant National Drug Control Program agency for implementing the strategy;




“(3)
 identify the specific resources required to enable the relevant National Drug Control Program agencies to implement the strategy; and




“(4)
 reflect the unique nature of small communities along the international border between the United States and Canada, ongoing cooperation and coordination with Canadian law enforcement authorities, and variations in the volumes of vehicles and pedestrians crossing through ports of entry along the international border between the United States and Canada.




“(d)
 
Specific Content Related to Cross-border Indian Reservations
.—
The Northern Border Counternarcotics Strategy shall include—
“(1)
 a strategy to end the illegal trafficking of drugs to or through Indian reservations on or near the international border between the United States and Canada; and




“(2)
 recommendations for additional assistance, if any, needed by tribal law enforcement agencies relating to the strategy, including an evaluation of Federal technical and financial assistance, infrastructure capacity building, and interoperability deficiencies.




“(e)
 Limitation.—
“(1)
 
In general
.—
The Northern Border Counternarcotics Strategy shall not change the existing agency authorities and this section shall not be construed to amend or modify any law governing interagency relationships.




“(2)
 
Legitimate trade and travel
.—
The Northern Border Counternarcotics Strategy shall be designed to promote, and not hinder, legitimate trade and travel.




“(f)
 Treatment of Classified or Law Enforcement Sensitive Information.—
“(1)
 
In general
.—
The Northern Border Counternarcotics Strategy shall be submitted in unclassified form and shall be available to the public.




“(2)
 
Annex
.—
The Northern Border Counternarcotics Strategy may include an annex containing any classified information or information the public disclosure of which, as determined by the Director or the head of any relevant National Drug Control Program agency, would be detrimental to the law enforcement or national security activities of any Federal, State, local, or tribal agency.”




 High Intensity Drug Trafficking Areas Program
(a)
 Establishment
(1)
 In general
There is established in the Office a program to be known as the High Intensity Drug Trafficking Areas Program (in this section referred to as the “Program”).






(2)
 Purpose
The purpose of the Program is to reduce drug trafficking and drug production in the United States by—
(A)
 facilitating cooperation among Federal, State, local, and tribal law enforcement agencies to share information and implement coordinated enforcement activities;




(B)
 enhancing law enforcement intelligence sharing among Federal, State, local, and tribal law enforcement agencies;




(C)
 providing reliable law enforcement intelligence to law enforcement agencies needed to design effective enforcement strategies and operations; and




(D)
 supporting coordinated law enforcement strategies which maximize use of available resources to reduce the supply of illegal drugs in designated areas and in the United States as a whole.






(b)
 Designation
(1)
 In general
The Director, in consultation with the Attorney General, the Secretary of the Treasury, the Secretary of Homeland Security, heads of the National Drug Control Program agencies, and the Governor of each applicable State, may designate any specified area of the United States as a high intensity drug trafficking area.






(2)
 Activities
After making a designation under paragraph (1) and in order to provide Federal assistance to the area so designated, the Director may—
(A)
 obligate such sums as are appropriated for the Program;




(B)
 direct the temporary reassignment of Federal personnel to such area, subject to the approval of the head of the department or agency that employs such personnel;




(C)
 take any other action authorized under 
section 1703 of this title
 to provide increased Federal assistance to those areas; and




(D)
 coordinate activities under this section (specifically administrative, recordkeeping, and funds management activities) with State, local, and tribal officials.






(c)
 Petitions for designation
The Director shall establish regulations under which a coalition of interested law enforcement agencies from an area may petition for designation as a high intensity drug trafficking area. Such regulations shall provide for a regular review by the Director of the petition, including a recommendation regarding the merit of the petition to the Director by a panel of qualified, independent experts.




(d)
 Factors for consideration
In considering whether to designate an area under this section as a high intensity drug trafficking area, the Director shall consider, in addition to such other criteria as the Director considers to be appropriate, the extent to which—
(1)
 the area is a significant center of illegal drug production, manufacturing, importation, or distribution;




(2)
 State, local, and tribal law enforcement agencies have committed resources to respond to the drug trafficking problem in the area, thereby indicating a determination to respond aggressively to the problem;




(3)
 drug-related activities in the area are having a significant harmful impact in the area, and in other areas of the country; and




(4)
 a significant increase in allocation of Federal resources is necessary to respond adequately to drug-related activities in the area.




(e)
 Organization of high intensity drug trafficking areas
(1)
 Executive Board and officers
To be eligible for funds appropriated under this section, each high intensity drug trafficking area shall be governed by an Executive Board. The Executive Board shall designate a chairman, vice chairman, and any other officers to the Executive Board that it determines are necessary.






(2)
 Responsibilities
The Executive Board of a high intensity drug trafficking area shall be responsible for—
(A)
 providing direction and oversight in establishing and achieving the goals of the high intensity drug trafficking area;




(B)
 managing the funds of the high intensity drug trafficking area;




(C)
 reviewing and approving all funding proposals consistent with the overall objective of the high intensity drug trafficking area; and




(D)
 reviewing and approving all reports to the Director on the activities of the high intensity drug trafficking area.






(3)
 Board representation
None of the funds appropriated under this section may be expended for any high intensity drug trafficking area, or for a partnership or region of a high intensity drug trafficking area, if the Executive Board for such area, region, or partnership, does not apportion an equal number of votes between representatives of participating Federal agencies and representatives of participating State, local, and tribal agencies. Where it is impractical for an equal number of representatives of Federal agencies and State, local, and tribal agencies to attend a meeting of an Executive Board in person, the Executive Board may use a system of proxy votes or weighted votes to achieve the voting balance required by this paragraph.






(4)
 No agency relationship
The eligibility requirements of this section are intended to ensure the responsible use of Federal funds. Nothing in this section is intended to create an agency relationship between individual high intensity drug trafficking areas and the Federal Government.






(f)
 Use of funds
The Director shall ensure that no Federal funds appropriated for the Program are expended for the establishment or expansion of drug treatment programs, and shall ensure that not more than 5 percent of the Federal funds appropriated for the Program are expended for the establishment of drug prevention programs.




(g)
 Counterterrorism activities
(1)
 Assistance authorized
The Director may authorize use of resources available for the Program to assist Federal, State, local, and tribal law enforcement agencies in investigations and activities related to terrorism and prevention of terrorism, especially but not exclusively with respect to such investigations and activities that are also related to drug trafficking.






(2)
 Limitation
The Director shall ensure—
(A)
 that assistance provided under paragraph (1) remains incidental to the purpose of the Program to reduce drug availability and carry out drug-related law enforcement activities; and




(B)
 that significant resources of the Program are not redirected to activities exclusively related to terrorism, except on a temporary basis under extraordinary circumstances, as determined by the Director.






(h)
 Role of Drug Enforcement Administration
The Director, in consultation with the Attorney General, shall ensure that a representative of the Drug Enforcement Administration is included in the Intelligence Support Center for each high intensity drug trafficking area.




(i)
 Annual HIDTA Program budget submissions
As part of the documentation that supports the President’s annual budget request for the Office, the Director shall submit to Congress a budget justification that includes—
(1)
 the amount proposed for each high intensity drug trafficking area, conditional upon a review by the Office of the request submitted by the HIDTA and the performance of the HIDTA, with supporting narrative descriptions and rationale for each request;




(2)
 a detailed justification that explains—
(A)
 the reasons for the proposed funding level; how such funding level was determined based on a current assessment of the drug trafficking threat in each high intensity drug trafficking area;




(B)
 how such funding will ensure that the goals and objectives of each such area will be achieved; and




(C)
 how such funding supports the National Drug Control Strategy; and






(3)
 the amount of HIDTA funds used to investigate and prosecute organizations and individuals trafficking in methamphetamine in the prior calendar year, and a description of how those funds were used.




(j)
 Emerging threat response fund
(1)
 In general
Subject to the availability of appropriations, the Director may expend up to 10 percent of the amounts appropriated under this section on a discretionary basis, to respond to any emerging drug trafficking threat in an existing high intensity drug trafficking area, or to establish a new high intensity drug trafficking area or expand an existing high intensity drug trafficking area, in accordance with the criteria established under paragraph (2).






(2)
 Consideration of impact
In allocating funds under this subsection, the Director shall consider—
(A)
 the impact of activities funded on reducing overall drug traffic in the United States, or minimizing the probability that an emerging drug trafficking threat will spread to other areas of the United States; and




(B)
 such other criteria as the Director considers appropriate.






(k)
 Evaluation
(1)
 Initial report
Not later than 90 days after 
December 29, 2006
, the Director shall, after consulting with the Executive Boards of each designated high intensity drug trafficking area, submit a report to Congress that describes, for each designated high intensity drug trafficking area—
(A)
 the specific purposes for the high intensity drug trafficking area;




(B)
 the specific long-term and short-term goals and objectives for the high intensity drug trafficking area;




(C)
 the measurements that will be used to evaluate the performance of the high intensity drug trafficking area in achieving the long-term and short-term goals; and




(D)
 the reporting requirements needed to evaluate the performance of the high intensity drug trafficking area in achieving the long-term and short-term goals.






(2)
 Evaluation of HIDTA Program as part of National Drug Control Strategy
For each designated high intensity drug trafficking area, the Director shall submit, as part of the annual National Drug Control Strategy report, a report that—
(A)
 describes—
(i)
 the specific purposes for the high intensity drug trafficking area; and




(ii)
 the specific long-term and short-term goals and objectives for the high intensity drug trafficking area; and






(B)
 includes an evaluation of the performance of the high intensity drug trafficking area in accomplishing the specific long-term and short-term goals and objectives identified under paragraph (1)(B).






(l)
 Assessment of drug enforcement task forces in high intensity drug trafficking areas
Not later than 1 year after 
December 29, 2006
, and as part of each subsequent annual National Drug Control Strategy report, the Director shall submit to Congress a report—
(1)
 assessing the number and operation of all federally funded drug enforcement task forces within each high intensity drug trafficking area; and




(2)
 describing—
(A)
 each Federal, State, local, and tribal drug enforcement task force operating in the high intensity drug trafficking area;




(B)
 how such task forces coordinate with each other, with any high intensity drug trafficking area task force, and with investigations receiving funds from the Organized Crime and Drug Enforcement Task Force;




(C)
 what steps, if any, each such task force takes to share information regarding drug trafficking and drug production with other federally funded drug enforcement task forces in the high intensity drug trafficking area;




(D)
 the role of the high intensity drug trafficking area in coordinating the sharing of such information among task forces;




(E)
 the nature and extent of cooperation by each Federal, State, local, and tribal participant in ensuring that such information is shared among law enforcement agencies and with the high intensity drug trafficking area;




(F)
 the nature and extent to which information sharing and enforcement activities are coordinated with joint terrorism task forces in the high intensity drug trafficking area; and




(G)
 any recommendations for measures needed to ensure that task force resources are utilized efficiently and effectively to reduce the availability of illegal drugs in the high intensity drug trafficking areas.






(m)
 Assessment of law enforcement intelligence sharing in High Intensity Drug Trafficking Areas Program
Not later than 180 days after 
December 29, 2006
, and as part of each subsequent annual National Drug Control Strategy report, the Director, in consultation with the Director of National Intelligence, shall submit to Congress a report—
(1)
 evaluating existing and planned law enforcement intelligence systems supported by each high intensity drug trafficking area, or utilized by task forces receiving any funding under the Program, including the extent to which such systems ensure access and availability of law enforcement intelligence to Federal, State, local, and tribal law enforcement agencies within the high intensity drug trafficking area and outside of it;




(2)
 the extent to which Federal, State, local, and tribal law enforcement agencies participating in each high intensity drug trafficking area are sharing law enforcement intelligence information to assess current drug trafficking threats and design appropriate enforcement strategies; and




(3)
 the measures needed to improve effective sharing of information and law enforcement intelligence regarding drug trafficking and drug production among Federal, State, local, and tribal law enforcement participating in a high intensity drug trafficking area, and between such agencies and similar agencies outside the high intensity drug trafficking area.




(n)
 Coordination of Law enforcement intelligence sharing with Organized Crime Drug Enforcement Task Force program
The Director, in consultation with the Attorney General, shall ensure that any drug enforcement intelligence obtained by the Intelligence Support Center for each high intensity drug trafficking area is shared, on a timely basis, with the drug intelligence fusion center operated by the Organized Crime Drug Enforcement Task Force of the Department of Justice.




(o)
 Use of funds to combat methamphetamine trafficking
(1)
 Requirement
As part of the documentation that supports the President’s annual budget request for the Office, the Director shall submit to Congress a report describing the use of HIDTA funds to investigate and prosecute organizations and individuals trafficking in methamphetamine in the prior calendar year.






(2)
 Contents
The report shall include—
(A)
 the number of methamphetamine manufacturing facilities discovered through HIDTA-funded initiatives in the previous fiscal year;




(B)
 the amounts of methamphetamine or listed chemicals (as that term is defined in 
section 802(33) of this title
 
1
1
 So in original. There probably should be a closing parenthesis.
 seized by HIDTA-funded initiatives in the area during the previous year; and




(C)
 law enforcement intelligence and predictive data from the Drug Enforcement Administration showing patterns and trends in abuse, trafficking, and transportation in methamphetamine and listed chemicals.






(3)
 Certification
Before the Director awards any funds to a high intensity drug trafficking area, the Director shall certify that the law enforcement entities participating in that HIDTA are providing laboratory seizure data to the national clandestine laboratory database at the El Paso Intelligence Center.






(p)
 Authorization of appropriations
There is authorized to be appropriated to the Office of National Drug Control Policy to carry out this section—
(1)
 $240,000,000 for fiscal year 2007;




(2)
 $250,000,000 for fiscal year 2008;




(3)
 $260,000,000 for fiscal year 2009;




(4)
 $270,000,000 for fiscal year 2010; and




(5)
 $280,000,000 for each of 
2
2
 So in original.
 fiscal year 2011.




(q)
 Specific purposes
(1)
 In general
The Director shall ensure that, of the amounts appropriated for a fiscal year for the Program, at least $7,000,000 is used in high intensity drug trafficking areas with severe neighborhood safety and illegal drug distribution problems.






(2)
 Required uses
The funds used under paragraph (1) shall be used—
(A)
 to ensure the safety of neighborhoods and the protection of communities, including the prevention of the intimidation of potential witnesses of illegal drug distribution and related activities; and




(B)
 to combat illegal drug trafficking through such methods as the Director considers appropriate, such as establishing or operating (or both) a toll-free telephone hotline for use by the public to provide information about illegal drug-related activities.






“(a)
 In General.—
“(1)
 
In general
.—
The Director of National Drug Control Policy shall use amounts available under this section to combat the trafficking of methamphetamine and amphetamine in areas designated by the Director as high intensity drug trafficking areas.




“(2)
 
Activities
.—
In meeting the requirement in paragraph (1), the Director shall transfer funds to appropriate Federal, State, and local governmental agencies for employing additional Federal law enforcement personnel, or facilitating the employment of additional State and local law enforcement personnel, including agents, investigators, prosecutors, laboratory technicians, chemists, investigative assistants, and drug-prevention specialists.




“(b)
 
Authorization of Appropriations
.—
There is authorized to be appropriated to carry out this section—
“(1)
 $15,000,000 for fiscal year 2000; and




“(2)
 such sums as may be necessary for each of fiscal years 2001 through 2004.




“(c)
 Apportionment of Funds.—
“(1)
 
Factors in apportionment
.—
The Director shall apportion amounts appropriated for a fiscal year pursuant to the authorization of appropriations in subsection (b) for activities under subsection (a) among and within areas designated by the Director as high intensity drug trafficking areas based on the following factors:
“(A)
 The number of methamphetamine manufacturing facilities and amphetamine manufacturing facilities discovered by Federal, State, or local law enforcement officials in the previous fiscal year.




“(B)
 The number of methamphetamine prosecutions and amphetamine prosecutions in Federal, State, or local courts in the previous fiscal year.




“(C)
 The number of methamphetamine arrests and amphetamine arrests by Federal, State, or local law enforcement officials in the previous fiscal year.




“(D)
 The amounts of methamphetamine, amphetamine, or listed chemicals (as that term is defined in section 102(33) of the Controlled Substances Act (
21 U.S.C. 802(33)
) seized by Federal, State, or local law enforcement officials in the previous fiscal year.




“(E)
 Intelligence and predictive data from the Drug Enforcement Administration and the Department of Health and Human Services showing patterns and trends in abuse, trafficking, and transportation in methamphetamine, amphetamine, and listed chemicals (as that term is so defined).






“(2)
 
Certification
.—
Before the Director apportions any funds under this subsection to a high intensity drug trafficking area, the Director shall certify that the law enforcement entities responsible for clandestine methamphetamine and amphetamine laboratory seizures in that area are providing laboratory seizure data to the national clandestine laboratory database at the El Paso Intelligence Center.




“(d)
 
Limitation on Administrative Costs
.—
Not more than 5 percent of the amount appropriated in a fiscal year pursuant to the authorization of appropriations for that fiscal year in subsection (b) may be available in that fiscal year for administrative costs associated with activities under subsection (a).”


 Counter-Drug Technology Assessment Center
(a)
 Establishment
There is established within the Office the Counter-Drug Technology Assessment Center (referred to in this section as the “Center”). The Center shall operate under the authority of the Director of National Drug Control Policy and shall serve as the central counter-drug technology research and development organization of the United States Government.




(b)
 Chief Scientist
There shall be at the head of the Center the Chief Scientist, who shall be appointed by the Director from among individuals qualified and distinguished in the area of science, medicine, engineering, or technology.




(c)
 Research and development responsibilities
The Director, acting through the Chief Scientist, shall—
(1)
 identify and define the short-, medium-, and long-term scientific and technological needs of Federal, State, local, and tribal drug supply reduction agencies, including—
(A)
 advanced surveillance, tracking, and radar imaging;




(B)
 electronic support measures;




(C)
 communications;




(D)
 data fusion, advanced computer systems, and artificial intelligence; and




(E)
 chemical, biological, radiological (including neutron and electron), and other means of detection;






(2)
 identify demand reduction basic and applied research needs and initiatives, in consultation with affected National Drug Control Program agencies, including—
(A)
 improving treatment through neuroscientific advances;




(B)
 improving the transfer of biomedical research to the clinical setting; and




(C)
 in consultation with the National Institute of Drug Abuse and the Substance Abuse and Mental Health Services Administration, and through interagency agreements or grants, examining addiction and rehabilitation research and the application of technology to expanding the effectiveness and availability of drug treatment;






(3)
 make a priority ranking of such needs identified in paragraphs (1) and (2) according to fiscal and technological feasibility, as part of a National Counterdrug Research and Development Program;




(4)
 oversee and coordinate counterdrug technology initiatives with related activities of other Federal civilian and military departments;




(5)
 provide support to the development and implementation of the national drug control performance measurement system established under subsection (c) of 
section 1705 of this title
; and




(6)
 pursuant to the authority of the Director of National Drug Control Policy under 
section 1703 of this title
, submit requests to Congress for the reprogramming or transfer of funds appropriated for counterdrug technology research and development.




(d)
 Limitation on authority
The authority granted to the Director under this section shall not extend to the awarding of contracts, management of individual projects, or other operational activities.




(e)
 Assistance and support to the Office of National Drug Control Policy
The Secretary of Defense, the Secretary of Homeland Security, and the Secretary of Health and Human Services shall, to the maximum extent practicable, render assistance and support to the Office and to the Director in the conduct of counterdrug technology assessment.




(f)
 Technology transfer program
(1)
 Program
The Chief Scientist, with the advice and counsel of experts from State, local, and tribal law enforcement agencies, shall be responsible to the Director for coordination and implementation of a counterdrug technology transfer program.






(2)
 Purpose
The purpose of the Technology Transfer Program shall be for the Counterdrug Technology Assessment Center to transfer technology and associated training directly to State, local, and tribal law enforcement agencies.






(3)
 Priority of receipts
Transfers shall be made in priority order based on—
(A)
 the need of potential recipients for such technology;




(B)
 the effectiveness of the technology to enhance current counterdrug activities of potential recipients; and




(C)
 the ability and willingness of potential recipients to evaluate transferred technology.






(4)
 Agreement authority
The Director may enter into an agreement with the Secretary of Homeland Security to transfer technology with both counterdrug and homeland security applications to State, local, and tribal law enforcement agencies on a reimbursable basis.






(5)
 Report
On or before July 1 of each year, the Director shall submit a report to the appropriate congressional committees that addresses the following:
(A)
 The number of requests received during the previous 12 months, including the identity of each requesting agency and the type of technology requested.




(B)
 The number of requests fulfilled during the previous 12 months, including the identity of each recipient agency and the type of technology transferred.




(C)
 A summary of the criteria used in making the determination on what requests were funded and what requests were not funded, except that such summary shall not include specific information on any individual requests.




(D)
 A general assessment of the future needs of the program, based on expected changes in threats, expected technologies, and likely need from potential recipients.




(E)
 An assessment of the effectiveness of the technologies transferred, based in part on the evaluations provided by the recipients, with a recommendation whether the technology should continue to be offered through the program.






 National youth anti-drug media campaign
(a)
 In general
The Director shall conduct a national youth anti-drug media campaign (referred to in this chapter 
1
1
 See References in Text note below.
 as the “national media campaign”) in accordance with this section for the purposes of—
(1)
 preventing drug abuse among young people in the United States;




(2)
 increasing awareness of adults of the impact of drug abuse on young people; and




(3)
 encouraging parents and other interested adults to discuss with young people the dangers of illegal drug use.




(b)
 Use of funds
(1)
 In general
Amounts made available to carry out this section for the national media campaign may only be used for the following:
(A)
 The purchase of media time and space, including the strategic planning for, and accounting of, such purchases.




(B)
 Creative and talent costs, consistent with paragraph (2)(A).




(C)
 Advertising production costs.




(D)
 Testing and evaluation of advertising.




(E)
 Evaluation of the effectiveness of the national media campaign.




(F)
 The negotiated fees for the winning bidder on requests for proposals issued either by the Office or its designee to enter into contracts to carry out activities authorized by this section.




(G)
 Partnerships with professional and civic groups, community-based organizations, including faith-based organizations, and government organizations related to the national media campaign.




(H)
 Entertainment industry outreach, interactive outreach, media projects and activities, public information, news media outreach, and corporate sponsorship and participation.




(I)
 Operational and management expenses.






(2)
 Specific requirements
(A)
 Creative services
(i)
 In using amounts for creative and talent costs under paragraph (1)(B), the Director shall use creative services donated at no cost to the Government (including creative services provided by the Partnership for a Drug-Free America) wherever feasible and may only procure creative services for advertising—
(I)
 responding to high-priority or emergent campaign needs that cannot timely be obtained at no cost; or




(II)
 intended to reach a minority, ethnic, or other special audience that cannot reasonably be obtained at no cost; or




(III)
 the Director determines that the Partnership for a Drug-Free America is unable to provide, pursuant to subsection (d)(2)(B).






(ii)
 Subject to the availability of appropriations, no more than $1,500,000 may be expended under this section each fiscal year on creative services, except that the Director may expend up to $2,000,000 in a fiscal year on creative services to meet urgent needs of the national media campaign with advance approval from the Committee on Appropriations of the Senate and of the House of Representatives upon a showing of the circumstances causing such urgent needs of the national media campaign.






(B)
 Testing and evaluation of advertising
In using amounts for testing and evaluation of advertising under paragraph (1)(D), the Director shall test all advertisements prior to use in the national media campaign to ensure that the advertisements are effective and meet industry-accepted standards. The Director may waive this requirement for advertisements using no more than 10 percent of the purchase of advertising time purchased under this section in a fiscal year and no more than 10 percent of the advertising space purchased under this section in a fiscal year, if the advertisements respond to emergent and time-sensitive campaign needs or the advertisements will not be widely utilized in the national media campaign.






(C)
 Evaluation of effectiveness of media campaign
In using amounts for the evaluation of the effectiveness of the national media campaign under paragraph (1)(E), the Director shall—
(i)
 designate an independent entity to evaluate by April 20 of each year the effectiveness of the national media campaign based on data from—
(I)
 the Monitoring the Future Study published by the Department of Health and Human Services;




(II)
 the Attitude Tracking Study published by the Partnership for a Drug-Free America;




(III)
 the National Household Survey on Drug Abuse; and




(IV)
 other relevant studies or publications, as determined by the Director, including tracking and evaluation data collected according to marketing and advertising industry standards; and






(ii)
 ensure that the effectiveness of the national media campaign is evaluated in a manner that enables consideration of whether the national media campaign has contributed to reduction of illicit drug use among youth and such other measures of evaluation as the Director determines are appropriate.








(3)
 Purchase of advertising time and space
Subject to the availability of appropriations, for each fiscal year, not less than 77 percent of the amounts appropriated under this section shall be used for the purchase of advertising time and space for the national media campaign, subject to the following exceptions:
(A)
 In any fiscal year for which less than $125,000,000 is appropriated for the national media campaign, not less than 72 percent of the amounts appropriated under this section shall be used for the purchase of advertising time and space for the national media campaign.




(B)
 In any fiscal year for which more than $195,000,000 is appropriated under this section, not less than 82 percent shall be used for advertising production costs and the purchase of advertising time and space for the national media campaign.






(c)
 Advertising
In carrying out this section, the Director shall ensure that sufficient funds are allocated to meet the stated goals of the national media campaign.




(d)
 Division of responsibilities and functions under the program
(1)
 In general
The Director, in consultation with the Partnership for a Drug-Free America, shall determine the overall purposes and strategy of the national media campaign.






(2)
 Responsibilities
(A)
 Director
The Director shall be responsible for implementing a focused national media campaign to meet the purposes set forth in subsection (a), and shall approve—
(i)
 the strategy of the national media campaign;




(ii)
 all advertising and promotional material used in the national media campaign; and




(iii)
 the plan for the purchase of advertising time and space for the national media campaign.






(B)
 The Partnership for a Drug-Free America
The Director shall request that the Partnership for a Drug-Free America—
(i)
 develop and recommend strategies to achieve the goals of the national media campaign, including addressing national and local drug threats in specific regions or States, such as methamphetamine and ecstasy;




(ii)
 create all advertising to be used in the national media campaign, except advertisements that are—
(I)
 provided by other nonprofit entities pursuant to subsection (f);




(II)
 intended to respond to high-priority or emergent campaign needs that cannot timely be obtained at no cost (not including production costs and talent reuse payments), provided that any such advertising material is reviewed by the Partnership for a Drug-Free America;




(III)
 intended to reach a minority, ethnic, or other special audience that cannot be obtained at no cost (not including production costs and talent reuse payments), provided that any such advertising material is reviewed by the Partnership for a Drug-Free America; or




(IV)
 any other advertisements that the Director determines that the Partnership for a Drug-Free America is unable to provide or if the Director determines that another entity is more appropriate, subject to the requirements of subsection (b)(2)(A).







If the Director determines that another entity is more appropriate under clause (ii)(IV), the Director shall notify Congress, through the committees of jurisdiction in the House and Senate, in writing, not less than 30 days prior to contracting with a party other than the Partnership for a Drug-Free America.




(C)
 Media buying contractor
The Director shall enter into a contract with a media buying contractor to plan and purchase advertising time and space for the national media campaign. The media buying contractor shall not provide any other service or material, or conduct any other function or activity which the Director determines should be provided by the Partnership for a Drug-Free America.








(e)
 Prohibitions
None of the amounts made available under subsection (b) may be obligated or expended for any of the following:
(1)
 To supplant current anti-drug community-based coalitions.




(2)
 To supplant pro bono public service time donated by national and local broadcasting networks for other public service campaigns.




(3)
 For partisan political purposes, or express advocacy in support of or to defeat any clearly identified candidate, clearly identified ballot initiative, or clearly identified legislative or regulatory proposal.




(4)
 To fund advertising that features any elected officials, persons seeking elected office, cabinet level officials, or other Federal officials employed pursuant to section 213 of Schedule C of title 5, Code of Federal Regulations.




(5)
 To fund advertising that does not contain a primary message intended to reduce or prevent illicit drug use.




(6)
 To fund advertising containing a primary message intended to promote support for the media campaign or private sector contributions to the media campaign.




(f)
 Matching requirement
(1)
 In general
Amounts made available under subsection (b) for media time and space shall be matched by an equal amount of non-Federal funds for the national media campaign, or be matched with in-kind contributions of the same value.






(2)
 No-cost match advertising direct relationship requirement
The Director shall ensure that at least 70 percent of no-cost match advertising provided directly relates to substance abuse prevention consistent with the specific purposes of the national media campaign, except that in any fiscal year in which less than $125,000,000 is appropriated to the national media campaign, the Director shall ensure that at least 85 percent of no-cost match advertising directly relates to substance abuse prevention consistent with the specific purposes of the national media campaign.






(3)
 No-cost match advertising not directly related
The Director shall ensure that no-cost match advertising that does not directly relate to substance abuse prevention consistent with the purposes of the national media campaign includes a clear anti-drug message. Such message is not required to be the primary message of the match advertising.






(g)
 Financial and performance accountability
The Director shall cause to be performed—
(1)
 audits and reviews of costs of the national media campaign pursuant to 
section 4706 of title 41
; and




(2)
 an audit to determine whether the costs of the national media campaign are allowable under chapter 43 of title 41.




(h)
 Report to Congress
The Director shall submit on an annual basis a report to Congress that describes—
(1)
 the strategy of the national media campaign and whether specific objectives of the media campaign were accomplished;




(2)
 steps taken to ensure that the national media campaign operates in an effective and efficient manner consistent with the overall strategy and focus of the national media campaign;




(3)
 plans to purchase advertising time and space;




(4)
 policies and practices implemented to ensure that Federal funds are used responsibly to purchase advertising time and space and eliminate the potential for waste, fraud, and abuse; and




(5)
 all contracts entered into with a corporation, partnership, or individual working on behalf of the national media campaign.




(i)
 Local target requirement
The Director shall, to the maximum extent feasible, use amounts made available under this section for media that focuses on, or includes specific information on, prevention or treatment resources for consumers within specific local areas.




(j)
 Prevention of marijuana use
(1)
 Findings
The Congress finds the following:
(A)
 60 percent of adolescent admissions for drug treatment are based on marijuana use.




(B)
 Potency levels of contemporary marijuana, particularly hydroponically grown marijuana, are significantly higher than in the past, rising from under 1 percent of THC in the mid-1970s to as high as 30 percent today.




(C)
 Contemporary research has demonstrated that youths smoking marijuana early in life may be up to 5 times more likely to use hard drugs.




(D)
 Contemporary research has demonstrated clear detrimental effects in adolescent educational achievement resulting from marijuana use.




(E)
 Contemporary research has demonstrated clear detrimental effects in adolescent brain development resulting from marijuana use.




(F)
 An estimated 9,000,000 Americans a year drive while under the influence of illegal drugs, including marijuana.




(G)
 Marijuana smoke contains 50 to 70 percent more of certain cancer causing chemicals than tobacco smoke.




(H)
 Teens who use marijuana are up to 4 times more likely to have a teen pregnancy than teens who have not.




(I)
 Federal law enforcement agencies have identified clear links suggesting that trade in hydroponic marijuana facilitates trade by criminal organizations in hard drugs, including heroin.




(J)
 Federal law enforcement agencies have identified possible links between trade in cannabis products and financing for terrorist organizations.






(2)
 Emphasis on prevention of youth marijuana use
In conducting advertising and activities otherwise authorized under this section, the Director may emphasize prevention of youth marijuana use.






(k)
 Prevention of methamphetamine abuse and other emerging drug abuse threats
(1)
 Requirement to use 10 percent of funds for methamphetamine abuse prevention
The Director shall ensure that, of the amounts appropriated under this section for the national media campaign for a fiscal year, not less than 10 percent shall be expended solely for the activities described in subsection (b)(1) with respect to advertisements specifically intended to reduce the use of methamphetamine.






(2)
 Authority to use funds for other drug abuse upon certification that methamphetamine abuse fell during fiscal year 2007
With respect to fiscal year 2008 and any fiscal year thereafter, if the Director certifies in writing to Congress that domestic methamphetamine laboratory seizures (as reported to the El Paso Intelligence Center of the Drug Enforcement Administration) decreased to at least 75 percent of the 2006 level, or the Director has documented a highly, statistically significant increase in a specific drug, from a baseline determined by locally collected data, that can be defined as a local drug crisis, the Director may apply paragraph (1)(A) for that fiscal year with respect to advertisements specifically intended to reduce the use of such other drugs.






(l)
 Authorization of appropriations
There is authorized to be appropriated to the Office to carry out this section, $195,000,000 for each of fiscal years 2007 and 2008 and $210,000,000 for each of fiscal years 2009 through 2011.




 Annual report requirement
(a)
 In general
On or before 
February 1, 2013
, and every 3 years thereafter,,
1
1
 So in original.
 the Director shall submit a report to Congress that describes—
(1)
 the strategy of the national media campaign and whether specific objectives of the campaign were accomplished;




(2)
 steps taken to ensure that the national media campaign operates in an effective and efficient manner consistent with the overall strategy and focus of the campaign;




(3)
 plans to purchase advertising time and space;




(4)
 policies and practices implemented to ensure that Federal funds are used responsibly to purchase advertising time and space and eliminate the potential for waste, fraud, and abuse;




(5)
 all contracts entered into with a corporation, partnership, or individual working on behalf of the national media campaign;




(6)
 specific policies and steps implemented to ensure compliance with title IV of this Act;




(7)
 steps taken to ensure that the national media campaign will secure, to the maximum extent possible, no cost matches of advertising time and space or in-kind contributions that are directly related to the campaign in accordance with title IV of this Act; and




(8)
 a review and evaluation of the effectiveness of the national media campaign strategy for the past year.




(b)
 Audit
The Government Accountability Office shall, not later than 
December 31, 2013
, and every 3 years thereafter—
(1)
 conduct and supervise an audit and investigation relating to the programs and operations of the—
(A)
 Office; or




(B)
 certain programs within the Office, including—
(i)
 the High Intensity Drug Trafficking Areas Program;




(ii)
 the Counterdrug Technology Assessment Center; or




(iii)
 the National Youth Anti-drug Media Campaign; and








(2)
 provide the Director and the appropriate congressional committees with a report containing an evaluation of and recommendations on the—
(A)
 policies and activities of the programs and operations subject to the audit and investigation;




(B)
 economy, efficiency, and effectiveness in the administration of the reviewed programs and operations; and




(C)
 policy or management changes needed to prevent and detect fraud and abuse in such programs and operations.






 Repealed. 
 Drug Interdiction Coordinator and Committee
(a)
 United States Interdiction Coordinator
(1)
 In general
The United States Interdiction Coordinator shall perform the duties of that position described in paragraph (2) and such other duties as may be determined by the Director with respect to coordination of efforts to interdict illicit drugs from entering the United States.






(2)
 Responsibilities
The United States Interdiction Coordinator shall be responsible to the Director for—
(A)
 coordinating the interdiction activities of the National Drug Control Program agencies to ensure consistency with the National Drug Control Strategy;




(B)
 on behalf of the Director, developing and issuing, on or before March 1 of each year and in accordance with paragraph (3), a National Interdiction Command and Control Plan to ensure the coordination and consistency described in subparagraph (A);




(C)
 assessing the sufficiency of assets committed to illicit drug interdiction by the relevant National Drug Control Program agencies; and




(D)
 advising the Director on the efforts of each National Drug Control Program agency to implement the National Interdiction Command and Control Plan.






(3)
 Staff
The Director shall assign such permanent staff of the Office as he considers appropriate to assist the United States Interdiction Coordinator to carry out the responsibilities described in paragraph (2), and may also, at his discretion, request that appropriate National Drug Control Program agencies detail or assign staff to the Office of Supply Reduction for that purpose.






(4)
 National Interdiction Command and Control Plan
(A)
 Purposes
The National Interdiction Command and Control Plan shall—
(i)
 set forth the Government’s strategy for drug interdiction;




(ii)
 state the specific roles and responsibilities of the relevant National Drug Control Program agencies for implementing that strategy; and




(iii)
 identify the specific resources required to enable the relevant National Drug Control Program agencies to implement that strategy.






(B)
 Consultation with other agencies
The United States Interdiction Coordinator shall issue the National Interdiction Command and Control Plan in consultation with the other members of the Interdiction Committee described in subsection (b).






(C)
 Limitation
The National Interdiction Command and Control Plan shall not change existing agency authorities or the laws governing interagency relationships, but may include recommendations about changes to such authorities or laws.






(D)
 Report to Congress
On or before March 1 of each year, the United States Interdiction Coordinator shall provide a report on behalf of the Director to the appropriate congressional committees, to the Committee on Armed Services and the Committee on Homeland Security of the House of Representatives, and to the Committee on Homeland Security and Governmental Affairs and the Committee on Armed Services of the Senate, which shall include—
(i)
 a copy of that year’s National Interdiction Command and Control Plan;




(ii)
 information for the previous 10 years regarding the number and type of seizures of drugs by each National Drug Control Program agency conducting drug interdiction activities, as well as statistical information on the geographic areas of such seizures; and




(iii)
 information for the previous 10 years regarding the number of air and maritime patrol hours undertaken by each National Drug Control Program agency conducting drug interdiction activities, as well as statistical information on the geographic areas in which such patrol hours took place.






(E)
 Treatment of classified or law enforcement sensitive information
Any content of the report described in subparagraph (D) that involves information classified under criteria established by an Executive order, or the public disclosure of which, as determined by the Director, the Director of National Intelligence, or the head of any Federal Government agency the activities of which are described in the plan, would be detrimental to the law enforcement or national security activities of any Federal, State, or local agency, shall be presented to Congress separately from the rest of the report.








(b)
 Interdiction Committee
(1)
 In general
The Interdiction Committee shall meet to—
(A)
 discuss and resolve issues related to the coordination, oversight and integration of international, border, and domestic drug interdiction efforts in support of the National Drug Control Strategy;




(B)
 review the annual National Interdiction Command and Control Plan, and provide advice to the Director and the United States Interdiction Coordinator concerning that plan; and




(C)
 provide such other advice to the Director concerning drug interdiction strategy and policies as the committee determines is appropriate.






(2)
 Chairman
The Director shall designate one of the members of the Interdiction Committee to serve as chairman.






(3)
 Meetings
The members of the Interdiction Committee shall meet, in person and not through any delegate or representative, at least once per calendar year, prior to March 1. At the call of either the Director or the current chairman, the Interdiction Committee may hold additional meetings, which shall be attended by the members either in person, or through such delegates or representatives as they may choose.






(4)
 Report
Not later than September 30 of each year, the chairman of the Interdiction Committee shall submit a report to the Director and to the appropriate congressional committees describing the results of the meetings and any significant findings of the Committee during the previous 12 months. Any content of such a report that involves information classified under criteria established by an Executive order, or whose public disclosure, as determined by the Director, the chairman, or any member, would be detrimental to the law enforcement or national security activities of any Federal, State, local, or tribal agency, shall be presented to Congress separately from the rest of the report.






 Requirement for disclosure of Federal sponsorship of all Federal advertising or other communication materials
(a)
 Requirement
Each advertisement or other communication paid for by the Office, either directly or through a contract awarded by the Office, shall include a prominent notice informing the target audience that the advertisement or other communication is paid for by the Office.




(b)
 Advertisement or other communication
In this section, the term “advertisement or other communication” includes—
(1)
 an advertisement disseminated in any form, including print or by any electronic means; and




(2)
 a communication by an individual in any form, including speech, print, or by any electronic means.




 Authorization of appropriations
There are authorized to be appropriated to carry out this chapter except activities otherwise specified, to remain available until expended, such sums as may be necessary for each of fiscal years 2006 through 2010.
 Termination of Office of National Drug Control Policy
(a)
 In general
Except as provided in subsection (b) of this section, effective on 
September 30, 2010
, this chapter and the amendments made to this chapter are repealed.




(b)
 Exception
Subsection (a) of this section does not apply to section 713 or the amendments made by that section.




 Authorization of use of environmentally-approved herbicides to eliminate illicit narcotics crops
The Secretary of State, the Attorney General, the Secretary of Agriculture, the Secretary of Defense, the Director of the Office of National Drug Control Policy, and the Administrator of the Environmental Protection Agency are authorized to support the development and use of environmentally-approved herbicides to eliminate illicit narcotics crops, including coca, cannabis, and opium poppy, both in the United States and in foreign countries.
 Awards for demonstration programs by local partnerships to coerce abstinence in chronic hard-drug users under community supervision through the use of drug testing and sanctions
(a)
 Awards required
The Director shall make competitive awards to fund demonstration programs by eligible partnerships for the purpose of reducing the use of illicit drugs by chronic hard-drug users living in the community while under the supervision of the criminal justice system.




(b)
 Use of award amounts
Award amounts received under this section shall be used—
(1)
 to support the efforts of the agencies, organizations, and researchers included in the eligible partnership;




(2)
 to develop and field a drug testing and graduated sanctions program for chronic hard-drug users living in the community under criminal justice supervision; and




(3)
 to assist individuals described in subsection (a) by strengthening rehabilitation efforts through such means as job training, drug treatment, or other services.




(c)
 Eligible partnership defined
In this section, the term “eligible partnership” means a working group whose application to the Director—
(1)
 identifies the roles played, and certifies the involvement of, two or more agencies or organizations, which may include—
(A)
 State, local, or tribal agencies (such as those carrying out police, probation, prosecution, courts, corrections, parole, or treatment functions);




(B)
 Federal agencies (such as the Drug Enforcement Agency, the Bureau of Alcohol, Tobacco, Firearms, and Explosives, and United States Attorney offices); and




(C)
 community-based organizations;






(2)
 includes a qualified researcher;




(3)
 includes a plan for using judicial or other criminal justice authority to administer drug tests to individuals described in subsection (a) at least twice a week, and to swiftly and certainly impose a known set of graduated sanctions for non-compliance with community-release provisions relating to drug abstinence (whether imposed as a pre-trial, probation, or parole condition or otherwise);




(4)
 includes a strategy for responding to a range of substance use and abuse problems and a range of criminal histories;




(5)
 includes a plan for integrating data infrastructure among the agencies and organizations included in the eligible partnership to enable seamless, real-time tracking of individuals described in subsection (a);




(6)
 includes a plan to monitor and measure the progress toward reducing the percentage of the population of individuals described in subsection (a) who, upon being summoned for a drug test, either fail to show up or who test positive for drugs.




(d)
 Reports to Congress
(1)
 Interim report
Not later than 
June 1, 2009
, the Director shall submit to Congress a report that identifies the best practices in reducing the use of illicit drugs by chronic hard-drug users, including the best practices identified through the activities funded under this section.






(2)
 Final report
Not later than 
June 1, 2010
, the Director shall submit to Congress a report on the demonstration programs funded under this section, including on the matters specified in paragraph (1).






(e)
 Authorization of appropriations
There is authorized to be appropriated to carry out this section $4,900,000 for each of fiscal years 2007 through 2009.




